Proteomic analysis of cancer associated proteins in the solid neoplasm -The analysis for individualized therapy for lung cancer-

1.基于凝胶的蛋白质组学(1)肺癌组织病理类型相关蛋白质分析：用双向凝胶电泳法(2DE)和质谱仪(MS)鉴定了47个蛋白质组分，其中腺癌相关蛋白15个，鳞癌相关蛋白16个，神经内分泌癌相关蛋白16个。验证分析正在进行中。(2)顺铂耐药相关蛋白分析：在2DE凝胶上检测到Gst-π和Rcn的斑点，并提出了术后选择铂类化疗有效者的可能性。此外，利用Ettan dige系统检测到10 7个蛋白质的表达水平高于1.5倍，1 2 0个蛋白质的表达水平低于0.75倍。(3)…检测到40个和33个蛋白质的表达水平发生了变化更多的是由两种酪氨酸激酶抑制剂。2.液-质联用蛋白质组学分析(1)肺腺癌淋巴结转移相关蛋白质的分析：比较T2no病例和T1n(+)病例的蛋白质表达谱。我们检测到604个与淋巴转移相关的候选蛋白。肺腺癌早期检测生物标志物的探索：通过对IA期和III期肺腺癌患者血清的分析，筛选出30种可用于早期检测的候选生物标志物。我们使用已经建立的检测系统验证了七种候选蛋白质。腺癌患者血清中某些候选蛋白的值升高，但与健康献血员相比差异无统计学意义。因此，我们没有认识到生物标记物在早期检测中的作用。基于蛋白质组图谱的分类很可能反映了癌细胞的生物学特性。我们安排进一步的调查和评估，为肺癌患者的个体化治疗提供后续和治疗策略。较少

1.Gel based proteomics(1)Analysis of proteins associated with histopathological types of lung cancer : 47 proteins (15 adenocarcinoma associated proteins, 16 squamous cell carcinoma associated proteins and 16 neuroendocrine carcinoma associated proteins) were identified using 2 dimensional polyacrylamide gel electrophoresis (2DE) and mass spectrometry (MS). The validation analysis is on going. We suggest the possibility of the classification based on proteomic profiles and the selection of the therapeutic strategy.(2)Analysis of CDDP resistance associated proteins : The spots of GST-π and reticulocalbin (RCN) were identified on 2DE gel, and we proposed the possibility that the responders for platinum based chemotherapy were selected postoperatively. Furthermore, we detected 107 proteins with more than 1.5 fold overexpression and 120 proteins with less than 0.75 fold reduced expression using Ettan DIGE System.(3)We detected 40 and 33 proteins in which the expression levels were changed … More by two kinds of tyrosine kinase inhibitors. These protein molecules were identified by MS, and sequentially we are carrying out the validation analysis.2.Proteomic analysis using Liquid Chromatography-MS (LC-MS)(1)Analysis of lymph node involvement associated proteins in lung adenocarcinoma : We compared protein expression profiles between t2 no cases and t1 n(+) cases. We detected 604 candidate proteins associated with lymph node involvement. The identification and validation are on going.(2)Exploration of the biomarkers for the early detection of lung adenocarcinoma : We analyzed sera of the patients with stage IA and stage III adenocarcinomas, and thirty candidate biomarkers for early detection were detected. We validated seven candidate proteins using already established assay systems. The values of some candidate proteins were elevated in the sera of adenocarcinoma patients, but there are no statistically significant differences between the sera of adenocarcinoma patients and healthy donors. Therefore, we did not recognize the usefulness of the biomarlcers for early detection.There is a high possibility that the classification based on proteomic profile reflects biological characteristics of cancerous cells. We schedule the further investigations and evaluations for the follow-up and therapeutic strategies towards the individualized therapy of lung cancer patients. Less